3D Cell Culture Market

The global 3D cell culture market in terms of revenue was estimated to be worth $1.3 billion in 2023 and is poised to reach $2.5 billion by 2028, growing at a CAGR of 14.6% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Rising incidence of chronic diseases, increasing demand for 3D cell culture due to increased demand for personalized medicine, strong emphasis on launch of novel products by key market players is driving the market growth.

Attractive Opportunities in the 3D cell culture market

To know about the assumptions considered for the study, Request for Free Sample Report

3D Cell Culture Market Dynamics

DRIVER: High focus on developing alternatives to animal testing

Animal studies are widely used in pharma and scientific research to investigate complex biological phenomena that cannot be studied with a simple two-dimensional (2D) cell culture. However, there has been a growing concern over the ethical and scientific limitations of relying solely on animal models for drug testing and toxicity screening. Additionally, animal testing is costly, time-consuming, and to a certain extent, may not accurately reflect human physiological responses. Due to the mentioned factors, pharmaceutical companies and research scientists are moving towards the adoption of alternatives to animal testing, such as 3D cell culture. 3D cell culture models provide a more human-relevant and predictive platform for studying drug efficacy and toxicity, reducing the reliance on animal models. These models offer a closer representation of human tissues and organs, allowing researchers to study the effects of drugs and potential toxicities in a more physiologically relevant environment.

Regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have encouraged the development and adoption of 3D cell culture globally for drug screening and safety assessment. For instance, in the FDA’s Predictive Toxicology Roadmap, the government promotes the use of advanced in vitro models, including 3D cell cultures, to improve the accuracy and efficiency of toxicity testing. The increasing regulatory scrutiny and the reduction of animal testing have spurred the adoption of 3D cell culture models across various industries, including pharmaceuticals, biotechnology, cosmetics, and chemicals. Increased investment by researchers and industry players in the development and optimization of 3D cell culture technologies to create more reliable and robust alternatives to animal testing drives the growth of the 3D cell culture industry.

RESTRAINT: High costs of implementing 3D cell culture technologies

The use of 3D cell culture is increasing rapidly owing to various factors such as advantages over 2D cell culture and a ban on animal testing in several countries, among others. However, the high cost of 3D cell culture is a major challenge to the growth of the market. The cost of implementing 3D cell culture technologies can vary depending on various factors, such as the complexity of the system, the scale of production, and the specific requirements of the application. The 3D cell culture laboratory includes various instruments and consumables used for the development of 3D cell models, such as CO2 incubators, bioreactors, microfluidic devices, and specialized imaging systems. The cost of these instruments can range from a few thousand dollars to several hundred thousand dollars, depending on the complexity and functionality required. For example, a basic CO2 incubator can cost around USD 2,000, whereas bioreactors can range from USD 10,000 to more than USD 100,000. The cost of cell culture depends on the cell source and maintenance requirements. Cell lines obtained from commercial repositories can range from a few USD 100 to more than USD 1000 per vial, depending on their characteristics and usage restrictions. Primary cells, on the other hand, can be more expensive owing to complexities in isolation and characterization. Additionally, the cost of maintaining cell cultures, including media changes, passage, and cryopreservation, is considered while calculating the overall cost of 3D cell culture models.

As a result of the high cost, 3D cell culture is adopted in large research institutions and pharmaceutical companies. This can limit the access that smaller research groups and individual researchers have to this technology. The high cost of 3D cell culture is a major barrier to the adoption of this technology by a wider range of users. As technology continues to develop and the cost of 3D cell culture decreases, it is likely that this technology will become more widely available to researchers and clinicians. The high cost of 3D cell culture is likely to hamper the market growth.  

OPPORTUNITY: Emergence of microfluidics-based 3D cell culture

Microfluidic-based cell culture is a type of cell culture that uses microfluidic devices to culture cells. These devices are small and miniaturized that can be used to control the flow of fluids, making them ideal for cell culture as they can be used to create controlled microenvironments for cells..

The advantages of microfluidic-based 3D cell culture has resulted in increased adoption across the globe. Researchers and pharmaceutical companies are using this platform to develop more accurate and reliable models for drug screening and toxicity testing. Microfluidic devices allows the integration of multiple cell types, creating complex cellular microenvironments that closely mimic in vivo conditions. This helps the study of cell-cell interactions, cell migration, and tissue development, leading to better insights into disease mechanisms and drug responses. Furthermore, the ability to generate organ-on-chip models, where different organs or tissues are connected in a microfluidic system, has obtained significant consideration. Organ-on-chip technology is likely to replace animal models for drug testing, as the technology offers a more realistic representation of human physiology and can be tailored to specific diseases or patient populations.

Key players operating in have adopted various organic and inorganic strategies in order to retain their market position. The companies have adopted statergies such as partnerships, collabrations with various research institutions. For instance, In July 2021, MIMETAS and Roche collaborated to develop human disease models to characterize novel compounds in inflammatory bowel disease (IBD) and hepatitis B virus infections (HBV). The adoption of microfluidic-based cell culture is anticipated to create lucrative growth opportunities in the market.

CHALLENGE: Lack of consistency and standardization in 3D cell culture products

There has been increased adoption of 3D cell culture products in research. However, lack of consistency in 3D cell culture products is one of the major challenge expected to hinder market growth. The various factors such as standardization challenges, variability in cell culture, quality control issues, scale up and manufacturing issues might hamper the market growth. With increasing demand for 3D cell culture products, there is a need for scalable manufacturing processes. However, transitioning from small-scale research laboratory production to large-scale manufacturing can introduce additional variables that may impact the consistency of the final product. Maintaining consistent conditions, reproducible results, and batch-to-batch consistency becomes more challenging as the scale increases. Furthermore, lack of standardized protocols and guidelines for producing and characterizing 3D cell culture model is likely to further hamper the market growth in coming years.

Apart from this, cell grown on low factor scaffolds are not approved for human application. This referes to the need of materials offering functionality of ECM and specificity in biological and material properties. However, synthetic marterilas is likely to address the challenges in coming years. Lack of inconsistency in the 3D cell culture products and regulations might hamper the market growth during the forecast period.

3D cell Culture Market Ecosystem

The scaffold-based 3D cell culture segment dominated the 3D cell culture industry 2022.

Based on product, the global 3D cell culture market is segmented into scaffold-based 3D cell cultures, scaffold-free 3D cell cultures, microfluidics-based 3D cell cultures, and magnetic & bioprinted 3D cell cultures segments. The scaffold-based 3D cell culture segment held the largest share in the overall market in 2022. The advantages of scaffolds in 3D cell cultures, such as structural rigidity, the availability of attachment points, and support, have greatly driven the preference for scaffold-based 3D cell cultures among end users and have ensured a large share of this segment.

Pharmaceutical & Biotechnology Companies segment dominated 3D cell culture industry in 2022

Based on end users, the 3D cell culture market is segmented into pharmaceutical & biotechnology companies, research institutes, cosmetics industry, and other end users. The pharmaceutical & biotechnology companies segment held the largest share in the market in 2022. Ban on animal testing, increased investment in R&D, and the rising adoption of personalized medicines are some of the key factors likely to have a positive impact on the market growth.

North America dominated the 3D cell culture industry in 2022.

To know about the assumptions considered for the study, download the pdf brochure

The global 3D cell culture market is segmented into five major regions—North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America held the largest share of in  the global market. The 3D cell culture industry in North America, especially in the US, benefits from its position as a prominent center for advanced R&D in biotechnology and pharmaceuticals. The region hosts a substantial number of academic institutions, research organizations, and biotech companies that are actively involved in exploring and advancing 3D cell culture techniques. The emphasis on creating groundbreaking cell culture models and methodologies is expected to be a significant driving force behind the market’s growth in the region.

In Europe, the adoption of 3D cell culture products is high in major end-user segments such as pharmaceutical & biotechnology companies and research institutes. Though this trend is expected to continue in the coming years, the adoption of these products is expected to be higher in the European market owing to the growth of the pharmaceutical & biotechnology industries, recent commercialization of microfluidic-based products, the increasing presence of major market players, and many research activities in the region.

Key players in the 3D cell culture market include Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Corning Incorporated (US), Lonza (Switzerland), Avantor Inc. (US), and others.

Scope of the 3D Cell Culture Industry

This report categorizes the 3D cell culture market to forecast revenue and analyze trends in each of the following submarkets:

By Product

• Scaffold-based 3D Cell Cultures
• Scaffold-free 3D Cell Cultures
• Microfluidics-based 3D Cell Cultures
• Magnetic & Bioprinted 3D Cell Cultures

By Application

• Cancer & Stem Cell Research
• Drug Discovery & Toxicology Testing
• Tissue Engineering & Regenerative Medicine

By End user

• Pharmaceutical & Biotechnology Companies
• Research Institutes
• Cosmetics Industry
• Other End Users

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia Pacific (APAC)
  • China
  • Japan
  • India
  • Rest of Asia Pacific (RoAPAC)
• Latin America (LATAM)
• Middle East and Africa (MEA)

Recent Developments of 3D Cell Culture Industry

• In October 2022, Corning launched the Elplasia 12K flask featuring a unique microcavity geometry that enables easy spheroid formation, culture, treatment, assessment, and harvest, with approximately 12,000 spheroids of uniform size and shape per flask, generating 125 times more yield than conventional 96-well spheroid plates.
• In March 2021, Thermo Fisher Scientific launched a plasma-like medium, a cell culture medium that mimics the metabolic profile of human plasma, designed to provide researchers with a realistic view of cell growth within the human body.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst